Envista Holdings Co. (NYSE:NVST) Stock Holdings Increased by Sterling Capital Management LLC

Sterling Capital Management LLC lifted its holdings in Envista Holdings Co. (NYSE:NVST) by 53.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 11,105 shares of the company’s stock after purchasing an additional 3,888 shares during the quarter. Sterling Capital Management LLC’s holdings in Envista were worth $214,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Venturi Wealth Management LLC grew its position in Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after buying an additional 1,638 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after acquiring an additional 538 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new position in shares of Envista in the fourth quarter valued at approximately $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Envista during the fourth quarter valued at approximately $86,000. Finally, KBC Group NV raised its holdings in Envista by 63.9% during the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after purchasing an additional 3,082 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on NVST shares. Jefferies Financial Group lifted their price target on Envista from $20.00 to $22.00 and gave the company a “hold” rating in a research report on Thursday, January 23rd. Morgan Stanley set a $16.00 price target on shares of Envista in a research report on Tuesday, April 15th. New Street Research set a $19.00 price objective on shares of Envista in a research report on Thursday, March 6th. UBS Group dropped their target price on shares of Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Monday, March 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Envista in a report on Thursday, March 6th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $19.96.

Envista Price Performance

NYSE NVST opened at $15.19 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -2.34, a price-to-earnings-growth ratio of 1.27 and a beta of 1.12. The company has a 50 day simple moving average of $17.82 and a 200-day simple moving average of $19.21. Envista Holdings Co. has a 52-week low of $14.22 and a 52-week high of $23.00.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. Equities research analysts predict that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.